Comparison Between Efficacy of Topical Sildenafil 2% & Topical Minoxidil

Status Recruiting

Clinical Trial Summary

Androgenetic alopecia (AGA) is hair loss with specific clinical pattern, It Is characterized by follicular miniaturization, which occurs due to systemic androgens and genetic factors. Prevalence differs according to ethnic groups. It is more common and more severe in white men than in Asian and black men. The incidence increases with age. According to Hamilton's study, the prevalence is 30% in men at the age of 30, and 50% in the age of 50. Generally, the age of onset is the 3rd and 4th decade.

Clinical Trial Description

Androgenetic alopecia may affect self-esteem and quality of life in several affected individuals. There are two FDA-approved drugs for pattern baldness: topical minoxidil and finasteride, both of which require at least a 4- to 6-month trial before noticing improvement and must be used indefinitely to maintain a response. As such, medication adherence often can be poor. Furthermore, initiation of the drug may cause an initial shedding phase. Minoxidil was the first and, so far, the only topical product that has been FDA approved for the treatment of AGA. Minoxidil was originally developed as an oral medication for hypertension. Hypertrichosis was found in 24-100 % of patients treated with oral minoxidil, which led to the treatment of AGA with topical minoxidil. Androgenic Alopecia is caused by the overproduction of 5αdihydrotestosterone (5α-DHT), a potent androgen within the hair follicle, specifically the dermal papilla (DP) cells that are the main regulators of hair growth and are the only site of 5α-DHT action. Sildenafil is a selective inhibitor of phosphodiesterase 5 and was originally developed as an anti-anginal drug due to its vasodilatory and antiplatelet coagulation properties. Sildenafil enhances the proliferation of human dermal papilla cells and up-regulates the mRNA expression of vascular endothelial growth factor and platelet-derived growth factor (PDGF) which are responsible for hair growth. Topical sildenafil 1% has been used in the treatment of male androgenic alopecia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05369481
Study type	Interventional
Source	Al-Azhar University
Contact	Yassir Hagag, MBBCH
Phone	+201021121721
Email	yassir_hagag@yahoo.com
Status	Recruiting
Phase	N/A
Start date	March 1, 2022
Completion date	September 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06110377` - MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine)	Phase 4
Recruiting	`NCT05611593` - Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia	Phase 1
Completed	`NCT03676400` - Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia	N/A
Recruiting	`NCT05938569` - Computer-Assisted Hair Restoration Study Using ARTAS System	N/A
Not yet recruiting	`NCT06326359` - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia	N/A
Recruiting	`NCT05426629` - Hydraderm for Androgenic Alopecia	Phase 4
Recruiting	`NCT05827991` - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia	N/A
Not yet recruiting	`NCT06292533` - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study	N/A
Completed	`NCT02824380` - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia	Phase 1
Completed	`NCT06112782` - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality	N/A
Completed	`NCT02594046` - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia	N/A
Recruiting	`NCT05435625` - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia	N/A
Completed	`NCT05450861` - Effect of the Composition From Fish on Promoting Hair Growth	N/A
Completed	`NCT03506503` - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia	N/A
Completed	`NCT03467412` - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin	Phase 2
Completed	`NCT01852487` - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia	N/A
Not yet recruiting	`NCT03474718` - Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia	Early Phase 1
Active, not recruiting	`NCT02914587` - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study	N/A
Completed	`NCT04341363` - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling	N/A
Completed	`NCT04450602` - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms